In 2020, within the framework of the transaction between JSC VTB Leasing and LLC Pharmasyntez-Tyumen, equipment for the production of drugs was put into operation in the amount of 1,2 billion rubles.

The world's leading manufacturers from different countries have been involved for the supply of the equipment:

● GEA Process Engineering NV Belgium (Belgium),

● Romaco Pharmatechnik GmbH (Germany),

● Shanghai Tofflon Science and Technology Co. Ltd (China),

● ACG Pharma Technologies PVT LTD (India).

«We are glad to take part in the implementation of such a significant social project for Russia and to make a contribution to the development of national production of medicines by offering the best conditions for financing and supply of the special-purpose equipment. In accordance with VTB's strategy, we support such important projects by conducting complex transactions with the most flexible financial parameters and optimal terms», said Dmitry Ivanter, CEO of the VTB Leasing Group.

Today, more than 95% of hormonal drugs are imported to Russia. With the launch of the plant in Tyumen, the import ratio will decrease by half, which corresponds to the global goal of the state program of import substitution «Pharma 2020».

The new production facility of the Pharmasyntez Group should become the largest infrastructure for the production of hormonal drugs in Russia. The total investment in launching the plant would be about 3,3 billion rubles. The plant will produce over 16 international non-proprietary names. The opening is scheduled for the first quarter of 2021.